Pluristem lack of disclosure on patient death in legal gray area, Bloomberg says Pluristem Therapeutics' (PSTI) stock soared and at least two top executives profited in spite of the fact that a patient reportedly died months after using its experimental stem cell treatment, according to Bloomberg. The company has yet to make an announcement of the girl’s death, which may put it in a legal gray area in regards to U.S. securities laws, the report noted. Reference Link
News For PSTI From The Last 14 Days
Check below for free stories on PSTI the last two weeks.